Vanta Bioscience Ltd Stock Price Today (NSE: VANTABIO)

Vanta Bioscience Ltd

23.75+0.15 (+0.64%)
Market Closed

Fundamental Score

...

Vanta Bioscience Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Vanta Bioscience Ltd share price today is 23.75, up +0.64% on NSE/BSE as of 17 June 2026. Vanta Bioscience Ltd (VANTABIO) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of 16.84 (Cr). The 52-week high for VANTABIO share price is 31.33 and the 52-week low is 14.71. The company has a Return on Equity (ROE) of -37.24% and a debt-to-equity ratio of 1.59.

Vanta Bioscience Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
24.45
Low
15.58
Volume
1.5K
Change
+50.46%

Vanta Bioscience Ltd share price chart: 50.46% return over the past month. 52-week high ₹31.33, 52-week low ₹14.71.

Vanta Bioscience Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
22.0722.0722.0722.07750.00 (Cr)
23.2323.2323.2323.230.00 (Cr)
23.2323.2323.2323.23750.00 (Cr)
24.4524.4524.4524.450.00 (Cr)
24.4524.4524.4524.45750.00 (Cr)
24.4524.4524.4524.45750.00 (Cr)
22.8022.8022.7022.704.50K (Cr)
19.5619.5619.5619.56750.00 (Cr)
17.0117.0117.0117.01750.00 (Cr)
18.0018.0018.0018.00750.00 (Cr)

Vanta Bioscience Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
23.2323.2322.0722.07-4.99%
18.3024.4515.5823.23+26.94%
17.9518.5015.2016.25-9.47%
15.0520.6014.7115.15+0.66%
19.8923.0016.2618.60-6.49%
22.2522.2519.4019.50-12.36%
22.5723.5016.8523.50+4.12%
23.9429.0022.5723.68-1.09%
23.0529.0021.6523.47+1.82%
22.0327.1521.8024.26+10.12%
26.8826.9823.1823.18-13.76%
26.4131.3326.4128.29+7.12%

Returns & Performance

Poor

Return on Equity (ROE)

-37.24%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-11.58%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

5.69%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Vanta Bioscience Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

45.95x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.81%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

12.08%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-70.87%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-32.27%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.59x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-2.69x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-43.40 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Vanta Bioscience Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of VANTABIO across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Balanced Promoter Holding (72.81%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (-37.24%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-11.58%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Revenue Contraction (-70.87%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-32.27% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Elevated Debt Levels (D/E: 1.59)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (-2.69x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-43.40 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Vanta Bioscience Ltd vs Healthcare Research, Analytics & Technology Peers

Peer Comparison - Healthcare Research, Analytics & Technology

Compare Vanta Bioscience Ltd with 8 other companies in the same sector

9 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
7.2/100
24
₹16.84
-37.24%
Poor
-11.58%
Poor
1.6
Average
-32.27%
Poor
0.00%
41.6/100
460
₹25985.68
55.5
Average
10.53%
Average
13.52%
Average
0.1
Excellent
5.71%
Good
12.60%
Good
0.19%
66.8/100
519
₹12660.10
28.4
Average
20.59%
Excellent
24.80%
Excellent
0.0
Excellent
67.93%
Excellent
34.59%
Excellent
0.38%
6.5/100
267
₹3927.58
-87.22%
Poor
-86.96%
Poor
0.0
Excellent
-24.19%
Poor
-12.00%
Poor
0.00%
65.8/100
457
₹2716.50
36.4
Average
19.43%
Good
25.22%
Excellent
0.0
Excellent
58.03%
Excellent
13.74%
Good
0.16%
19.5/100
31
₹481.24
120.6
Average
644.12%
Excellent
11.24%
Average
0.0
Excellent
38.14%
Excellent
0.00%
6.9/100
62
₹200.42
-5.58%
Poor
1.10%
Poor
1.5
Average
13.81%
Good
-15.48%
Poor
0.00%
40.6/100
57
₹101.70
104.8
Average
0.64%
Poor
0.96%
Poor
0.0
Excellent
-2.33%
Poor
82.92%
Excellent
0.00%
29.2/100
18
₹25.54
12.3
Average
5.51%
Poor
8.27%
Poor
0.2
Excellent
-1.36%
Poor
8.33%
Good
0.00%

Vanta Bioscience Ltd Quarterly Performance

Latest quarterly metrics for VANTABIO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-70.87%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

12.08%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-32.27%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Vanta Bioscience Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for VANTABIO — calculated from daily price history

67RSI 14
Neutral — RSI 67

Momentum is balanced — neither overbought nor oversold.

SMA 50
19
▲ Price above SMA 50 — Short-term bullish
SMA 200
25
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
4K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Vanta Bioscience Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Vanta Bioscience Ltd (VANTABIO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Vanta Bioscience Ltd

About VANTABIO (Vanta Bioscience Ltd)

Vanta Bioscience Ltd is a cutting-edge healthcare research organization dedicated to accelerating drug discovery and development through advanced analytics and innovative technolog...ies. We provide comprehensive preclinical research services, leveraging state-of-the-art facilities and a team of expert scientists to deliver robust and reliable data. Our expertise spans a wide range of disciplines, including molecular biology, pharmacology, toxicology, and bioanalysis. By integrating sophisticated analytical tools with deep scientific knowledge, we empower our clients to make informed decisions, optimize their research strategies, and ultimately bring life-changing therapies to market faster. At Vanta Bioscience, we are committed to delivering excellence at every stage of the preclinical research process. Our services include specialized assay development, validation, and execution of in vitro and in vivo studies, tailored to meet the unique needs of our clients. We utilize advanced techniques such as genomics, proteomics, and metabolomics to gain deeper insights into disease mechanisms and drug action. Furthermore, we offer comprehensive regulatory support, ensuring compliance with international guidelines and standards. Our goal is to be a trusted partner for pharmaceutical, biotechnology, and agrochemical companies, enabling them to overcome scientific challenges and achieve their research goals. Vanta Bioscience leverages its unique combination of scientific expertise, technological innovation, and rigorous quality control to provide actionable insights for our clients. We believe in the power of data-driven decision-making and continually invest in cutting-edge technologies to enhance our capabilities. From target identification to lead optimization, we offer a complete suite of services to support the entire preclinical drug development pipeline. By partnering with Vanta Bioscience, our clients gain access to a world-class research team, advanced analytical tools, and a commitment to delivering high-quality results that accelerate the development of innovative healthcare solutions.

Company Details

Symbol:VANTABIO
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology

Key Leadership

Mr. Dopesh Raja Mulakala
MD & Director
Mr. Venkata Sathya Murali Dokka
Chief Financial Officer
Mr. Mangesh Joshi
Vice President of HR & Admin

VANTABIO Share Price: Frequently Asked Questions

What is the current share price of Vanta Bioscience Ltd?

Vanta Bioscience Ltd (VANTABIO) trades at ₹23.75 on NSE and BSE. Market cap ₹16.84 (Cr). Educational data only.

What is the P/E ratio of Vanta Bioscience Ltd?

Vanta Bioscience Ltd has a P/E of N/Ax vs industry average 45.95x.

What is the Bull Run score for Vanta Bioscience Ltd?

Vanta Bioscience Ltd has a Bull Run score of 7.2/100 based on 25+ financial parameters.

Does Vanta Bioscience Ltd pay dividends?

Vanta Bioscience Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Vanta Bioscience Ltd?

Vanta Bioscience Ltd has ROE of -37.24%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Vanta Bioscience Ltd?

Vanta Bioscience Ltd has debt-to-equity of 1.59.

Is Vanta Bioscience Ltd a good investment?

Bull Run gives Vanta Bioscience Ltd a score of 7.2/100. This is not investment advice — consult a SEBI-registered advisor.